{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:42:04Z","timestamp":1770813724966,"version":"3.50.1"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Torrent Pharmaceuticals Limited","award":["Not appicable"],"award-info":[{"award-number":["Not appicable"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type-2-diabetes-mellitus (T2DM), often linked to obesity, raises risk of microvascular and macrovascular complications. International guidelines recommend triple-therapy to reach haemoglobin A1c (HbA1c) targets when dual therapy fails to adequately control blood glucose levels. Sitagliptin, enhances glycaemic control by prolonging incretin action, boosting insulin secretion, and lowering glucagon levels. When combined with glimepiride and metformin this triple-therapy targets multiple mechanisms. This study evaluated the effectiveness and safety of this combination for improved T2DM management in Indian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This real-world, multicentre, observational chart review evaluated the efficacy and safety of a triple fixed-dose combination therapy in 1235 adult patients with T2DM across 194 clinical sites in India. Data were retrospectively extracted from patient records over a 12-week period. Descriptive and analytical statistics was applied for the study endpoints using SPSS ver. 29.0.1.0(171) and Microsoft Excel 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>The study population had a mean age of 56.89\u2009\u00b1\u200910.29 years, with 64.70% reporting a family history of type 2 diabetes mellitus (T2DM). Smoking was identified as a prominent risk factor, affecting 38.65% of participants. Significant improvements were observed in glycemic parameters over 12 weeks: HbA1c levels decreased from 8.20\u2009\u00b1\u20090.60% to 7.08\u2009\u00b1\u20090.77% (p\u2009&lt;\u20090.0001), fasting blood glucose (FBG) from 188.54\u2009\u00b1\u200947.59\u2009mg\/dL to 146.01\u2009\u00b1\u200941.53\u2009mg\/dL (p\u2009&lt;\u20090.0001), and 2-hour postprandial plasma glucose (PPG) from 234.74\u2009\u00b1\u200950.40\u2009mg\/dL to 179.40\u2009\u00b1\u200942.51\u2009mg\/dL (p\u2009&lt;\u20090.0001). Additionally, body weight significantly reduced from 75.99\u2009\u00b1\u20098.67\u2009kg to 74.76\u2009\u00b1\u20099.07\u2009kg (p\u2009&lt;\u20090.0001). No significant safety concerns identified during the treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The triple-combination therapy (sitagliptin, glimepiride, and metformin) demonstrated superior efficacy in achieving glycemic control, as evidenced by significant reductions in HbA1c, fasting blood glucose (FBG), and postprandial plasma glucose (PPG). Furthermore, the therapy facilitated meaningful weight reduction, highlighting its clinical utility as a comprehensive therapeutic option for managing glycemic parameters in both T2DM with overweight and normal-weight patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0337107","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:33:22Z","timestamp":1770402802000},"page":"e0337107","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes"],"prefix":"10.1371","volume":"21","author":[{"given":"Kunal","family":"Zaveri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-0217","authenticated-orcid":true,"given":"Girish","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1990-8878","authenticated-orcid":true,"given":"Rathish","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Govarthanan","family":"Shanmugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubhada Amol","family":"Dharmadhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. P. S.","family":"Makkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Jalgaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. D.","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-0230","authenticated-orcid":true,"given":"Krishnaprasad","family":"Korukonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"GLIMSI Investigator(s) Study Panel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"5","key":"pone.0337107.ref001","article-title":"Retrospective observational study on assessing sitagliptin and dapagliflozin as a fixed-dose combination in the indian population with type 2 diabetes mellitus: the SIDAXA study","volume":"16","author":"M Chawla","year":"2024","journal-title":"Cureus"},{"key":"pone.0337107.ref002","unstructured":"Shamanna P, Jha PK, Makwana A, Shukla H, Bavishi C. Observational, Multicenter, Retrospective, Study on the Usage Patterns of the Fixed Dose Combination of Glimepiride, Metformin, and Voglibose in Type 2 Diabetes Management. Cureus. 16: e52064. doi:10.7759\/cureus.520643."},{"issue":"1","key":"pone.0337107.ref003","doi-asserted-by":"crossref","DOI":"10.2174\/1573399819666230413094200","article-title":"Prevalence of diabetes in India: a review of IDF diabetes Atlas 10th edition","volume":"20","author":"A Kumar","year":"2024","journal-title":"Curr Diabetes Rev"},{"key":"pone.0337107.ref004","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"RA DeFronzo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"pone.0337107.ref005","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1038\/s41598-024-55556-x","article-title":"Predictors of microvascular complications in patients with type 2 diabetes mellitus at regional referral hospitals in the central zone, Tanzania: a cross-sectional study","volume":"14","author":"WB Shillah","year":"2024","journal-title":"Sci Rep"},{"issue":"17","key":"pone.0337107.ref006","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of Type 2 diabetes mellitus","volume":"21","author":"U Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"pone.0337107.ref007","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"RA Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"pone.0337107.ref008","volume-title":"American diabetes association releases 2023 standards of care in diabetes to guide prevention, diagnosis, and treatment for people living with diabetes","author":"R Fisher","year":"2022"},{"key":"pone.0337107.ref009","first-page":"1","article-title":"RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022","volume":"42","year":"2022","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"1","key":"pone.0337107.ref010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3803\/EnM.2023.1816","article-title":"Initial combination therapy in type 2 diabetes","volume":"39","author":"JY Kim","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"11","key":"pone.0337107.ref011","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"MJ Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"pone.0337107.ref012","article-title":"Sitagliptin as an add-on therapy to other glucose-lowering agents in patients with type 2 diabetes mellitus: a narrative review","volume":"73","author":"S Kalra","year":"2025","journal-title":"J Assoc Physicians India"},{"issue":"4","key":"pone.0337107.ref013","article-title":"Real-world assessment of personalized approach with voglibose fixed-dose combination in type 2 diabetes mellitus","volume":"16","author":"N Parmar","year":"2024","journal-title":"Cureus"},{"key":"pone.0337107.ref014","first-page":"6","article-title":"Comparison of sitagliptin, glimepiride, and metformin group with glimepiride and metformin group in treatment of diabetes mellitus type 2 patients","volume":"1","author":"MF Hameed","year":"2022","journal-title":"J Pharmacol Drug Dev"},{"key":"pone.0337107.ref015","article-title":"Clinical experience with triple drug combination efficacy and patient treatment survey","author":"N Vijay","year":"2025","journal-title":"Indian J Clin Pract"},{"issue":"1","key":"pone.0337107.ref016","doi-asserted-by":"crossref","first-page":"01","DOI":"10.33545\/26649284.2024.v6.i1a.6","article-title":"Expert opinion on fixed-dose combinations of Sitagliptin + metformin and the triple drug combination of Voglibose + Glimepiride + Metformin in the management of type 2 diabetes mellitus in Indian settings","volume":"6","author":"S Manjula","year":"2024","journal-title":"Int J Endocrinol Sci"},{"issue":"5","key":"pone.0337107.ref017","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4093\/dmj.2017.41.5.337","article-title":"Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean diabetes association","volume":"41","author":"SH Ko","year":"2017","journal-title":"Diabetes Metab J"},{"issue":"11","key":"pone.0337107.ref018","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1345\/aph.1R041","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis","volume":"46","author":"H Park","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"4","key":"pone.0337107.ref019","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis","volume":"56","author":"YG Kim","year":"2013","journal-title":"Diabetologia"},{"issue":"5","key":"pone.0337107.ref020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4103\/ijem.IJEM_176_17","article-title":"Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: indian multicentric randomized trial - START study","volume":"21","author":"TV Devarajan","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"issue":"9","key":"pone.0337107.ref021","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1111\/dom.15705","article-title":"Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-na\u00efve patients with type 2 diabetes (TRIPLE-AXEL study): a multicentre, randomized, 104-week, open-label, active-controlled trial","volume":"26","author":"NH Kim","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"pone.0337107.ref022","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"K Hermansen","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"pone.0337107.ref023","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/1753-0407.12456","article-title":"Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin","volume":"9","author":"J Ba","year":"2016","journal-title":"Journal of Diabetes"},{"key":"pone.0337107.ref024","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.1461","article-title":"Triple therapy in type 2 diabetes; a systematic review and network meta-analysis","volume":"3","author":"MJ Downes","year":"2015","journal-title":"PeerJ"},{"key":"pone.0337107.ref025","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/jdi.13277","article-title":"Efficacy and safety of metformin and sitagliptin\u2010based dual and triple therapy in elderly Chinese patients with type 2 diabetes: subgroup analysis of STRATEGY study","volume":"11","author":"X Liu","year":"2020","journal-title":"J of Diabetes Invest"},{"issue":"8","key":"pone.0337107.ref026","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"BJ Goldstein","year":"2007","journal-title":"Diabetes Care"},{"issue":"7","key":"pone.0337107.ref027","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40618-018-0991-0","article-title":"Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea","volume":"42","author":"P Khaloo","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"pone.0337107.ref028","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"G Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"issue":"10","key":"pone.0337107.ref029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017260","article-title":"Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis","volume":"7","author":"M Sharma","year":"2017","journal-title":"BMJ Open"},{"key":"pone.0337107.ref030","doi-asserted-by":"crossref","first-page":"107517","DOI":"10.1016\/j.phrs.2024.107517","article-title":"Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study","volume":"210","author":"C Berra","year":"2024","journal-title":"Pharmacol Res"},{"issue":"3","key":"pone.0337107.ref031","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/cd18-0040","article-title":"Importance of postprandial glucose in relation to A1C and cardiovascular disease","volume":"37","author":"KS Hershon","year":"2019","journal-title":"Clin Diabetes"},{"issue":"10","key":"pone.0337107.ref032","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2337\/dc10-2414","article-title":"Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga diabetes study","volume":"34","author":"F Cavalot","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"pone.0337107.ref033","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2337\/dc08-2209","article-title":"Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer?","volume":"32","author":"A Ceriello","year":"2009","journal-title":"Diabetes Care"},{"issue":"7258","key":"pone.0337107.ref034","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"IM Stratton","year":"2000","journal-title":"BMJ"},{"key":"pone.0337107.ref035","article-title":"A summary of the ADVANCE Trial","author":"SR Heller","year":"2009","journal-title":"Diabetes Care"},{"issue":"4","key":"pone.0337107.ref036","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1751-7176.2011.00447.x","article-title":"Value of Angiotensin receptor blocker therapy in diabetes","volume":"13","author":"JL Izzo","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"pone.0337107.ref037","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1159\/000489913","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis","volume":"43","author":"K Wang","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"pone.0337107.ref038","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejim.2023.07.023","article-title":"The higher the serum albumin, the better? Findings from the PRACTICE study","volume":"116","author":"Y-Y Zheng","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"1","key":"pone.0337107.ref039","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12882-023-03110-8","article-title":"The level of serum albumin is associated with renal prognosis and renal function decline in patients with chronic kidney disease","volume":"24","author":"T Cheng","year":"2023","journal-title":"BMC Nephrol"},{"key":"pone.0337107.ref040","doi-asserted-by":"crossref","first-page":"107635","DOI":"10.1016\/j.phrs.2025.107635","article-title":"Pharmacological regression of atherosclerotic plaque in patients with type 2 diabetes","volume":"213","author":"L Bucciarelli","year":"2025","journal-title":"Pharmacol Res"},{"issue":"9","key":"pone.0337107.ref041","article-title":"Glimepiride and metformin combinations in diabetes comorbidities and complications: real-world evidence","volume":"12","author":"RK Sahay","year":"2020","journal-title":"Cureus"},{"issue":"9","key":"pone.0337107.ref042","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00592-023-02115-x","article-title":"AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus","volume":"60","author":"C Berra","year":"2023","journal-title":"Acta Diabetol"},{"issue":"2","key":"pone.0337107.ref043","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41591-022-02120-7","article-title":"Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study","volume":"29","author":"BM Shields","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"pone.0337107.ref044","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0149-2918(02)85047-0","article-title":"Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy","volume":"24","author":"C Melikian","year":"2002","journal-title":"Clin Ther"},{"issue":"15","key":"pone.0337107.ref045","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"K Makrilakis","year":"2019","journal-title":"IJERPH"},{"key":"pone.0337107.ref046","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.13137","article-title":"Efficacy of glucagon\u2010like peptide\u20101 receptor agonists compared to dipeptidyl peptidase\u20104 inhibitors for the management of type 2 diabetes: a meta\u2010analysis of randomized clinical trials","volume":"20","author":"S Tran","year":"2018","journal-title":"Diabetes Obesity Metabolism"},{"issue":"2","key":"pone.0337107.ref047","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","volume":"38","author":"AJ Scheen","year":"2012","journal-title":"Diabetes Metab"},{"issue":"3","key":"pone.0337107.ref048","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3111\/13696998.2015.1109518","article-title":"A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs","volume":"19","author":"T Lokhandwala","year":"2016","journal-title":"J Med Econ"},{"issue":"2","key":"pone.0337107.ref049","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s40200-024-01488-2","article-title":"A new glucose monitoring system for the intermittent monitoring of interstitial glucose values in patients with diabetes mellitus","volume":"23","author":"A Rossi","year":"2024","journal-title":"J Diabetes Metab Disord"},{"key":"pone.0337107.ref050","doi-asserted-by":"crossref","first-page":"111011","DOI":"10.1016\/j.diabres.2023.111011","article-title":"Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system","volume":"206","author":"A Rossi","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"pone.0337107.ref051","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae476","article-title":"Vaccinome landscape in nearly 620 000 patients with diabetes","volume":"110","author":"F D\u2019Addio","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:33:29Z","timestamp":1770402809000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337107"}},"subtitle":[],"editor":[{"given":"Natural Hoi Sing","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0337107","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}